Patient-Reported Outcomes from the Phase 3, Randomized Study of Acalabrutinib with or without Obinutuzumab versus Chlorambucil plus Obinutuzumab for Treatment-Naive Chronic Lymphocytic Leukemia (ELEVATE-TN)

December 2021 Vol 12, No 12
P Walker
Peninsula Health, and Peninsula Private Hospital, Frankston, Victoria, Australia, and Alfred Health, Melbourne, Victoria, Australia
JP Sharman
Willamette Valley Cancer Institute/US Oncology, Eugene, OR, USA
W Jurczak
Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland
T Munir
St James’s Institute of Oncology, Leeds, UK
V Banerji
Max Rady Faculty of Health Sciences, College of Medicine, University of Manitoba, and Research Institute in Oncology and Hematology, and CancerCare Manitoba, Winnipeg, MB, Canada
S Coutre
Stanford University School of Medicine, Stanford, CA, USA
JA Woyach
The Ohio State University Comprehensive Cancer Center and Division of Hematology, Columbus, OH, USA
G Salles
Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d’Hématologie Clinique, Pierre-Bénite, France
WG Wierda
The University of Texas MD Anderson Cancer Center, Houston, TX, USA
P Patel
AstraZeneca, South San Francisco, CA, USA
MH Wang
AstraZeneca, South San Francisco, CA, USA
U Emeribe
AstraZeneca, Gaithersburg, MD, USA
E Flood
AstraZeneca, Gaithersburg, MD, USA
JC Byrd
The Ohio State University Comprehensive Cancer Center and Division of Hematology, Columbus, OH, USA
P Ghia
Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milano, Italy

Background: Acalabrutinib is a potent, highly selective Bruton tyrosine kinase inhibitor approved for chronic lymphocytic leukemia (CLL) and previously treated mantle-cell lymphoma. In the pivotal ELEVATE-TN study, acalabrutinib (± obinutuzumab) demonstrated significant improvements in progression-free survival (PFS) versus chemoimmunotherapy in treatment-naive (TN) CLL after a median follow-up of 28.3 months.1 Patient-reported outcomes (PRO) data from ELEVATE- TN are reported here using the same data cutoff as the primary efficacy results.

Objective: Report PRO of fatigue and health-related quality of life (HRQoL) from the randomized, phase 3, ELEVATE-TN study (NCT02475681) in patients with TN CLL.

Methods: Patients received acalabrutinib alone (A), A plus obinutuzumab (AO), or chlorambucil plus obinutuzumab (CO). Assessments included the FACIT-Fatigue Global Fatigue Score (GFS) (scale: 0-52; lower score = worse outcome [clinically meaningful improvement: ≥+3]) and the EORTC QLQ-C30 Global Health Status (GHS) score (scale: 0-100; lower score = worse HRQoL [clinically meaningful improvement: >+8]) in all patients (excluding those who progressed) and those with severe fatigue at baseline (GFS ≤34), analyzed using mixed-model repeated measures methodology. A post hoc analysis assessed time to clinically meaningful deterioration (TTD; change ≤−3) in GFS.

Results: Among 535 randomized patients, 449 completed the GFS (A, n = 156; AO, n = 152; CO, n = 141) and 450 completed the GHS (A, n = 157; AO, n = 151; CO, n = 142) at baseline. Overall, 151 randomized patients had severe fatigue (A, n = 56; AO, n = 53; CO, n = 42); all completed both questionnaires at baseline. In all arms, GFS and GHS improvements were observed by week 4 (mean changes: 2.76 and 5.35 for A [n = 136, n = 137], 2.33 and 2.17 for AO [n = 138, n = 138], 1.26 and 2.53 for CO [n = 121, n = 122]) and maintained at 96 weeks (4.94 and 7.01 for A [n = 81, n = 82], 3.91 and 5.25 for AO [n = 92, n = 92], 3.86 and 2.41 for CO [n = 38, n = 38]); this benefit was larger in patients with severe fatigue. Median TTD in fatigue was longer in acalabrutinib-containing arms (A: 16.9 mo; AO: 16.7 mo) versus CO (5.7 mo [P = .0376 vs A; P = .1596 vs AO]).

Conclusions: In ELEVATE-TN, all treatments improved fatigue scores; TTD of fatigue was significantly longer with acalabrutinib-containing treatment. The previously reported statistically significant PFS increases with A/AO versus CO were accompanied by clinically meaningful HRQoL benefits.


  1. Sharman JP, Egyed M, Jurczaket W, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020;395:1278-1291.
Related Articles
Assessment of Side Effects (SEs) Impacting Quality of Life (QOL) in Patients (Pts) Undergoing Treatment (tx) for Advanced Breast Cancer (ABC) in Clinical Practice: A Real-World (RW) Multicountry Survey
November 2022 Vol 13, No 11
To examine how SEs impacting QOL in pts with ABC are perceived.
Intracranial Activity of Tepotinib in Patients with MET Exon 14 (METex14) Skipping Non–Small-Cell Lung Cancer (NSCLC) Enrolled in VISION
November 2022 Vol 13, No 11
To provide analysis of the intracranial activity of tepotinib in patients with METex14 skipping NSCLC with BM from the VISION study to aid oncology nurse navigators who manage this population of patients.
MOMENTUM: Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor
November 2022 Vol 13, No 11
MF is a rare bone marrow cancer characterized by fibrosis, abnormal blood cell production, and dysregulated JAK/STAT signaling.1,2
Last modified: August 10, 2023

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
    Profession or Role
    Primary Specialty or Disease State